Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript Summary
Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript Summary
Loss from operations decreased 22% to $3.6 million.The following is a summary of the Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript:
以下是apyx medical公司（APYX）2024年第三季度业绩会议电话记录摘要：
Financial Performance:
财务表现:
Reported a total quarterly revenue of $11.5 million, a decrease of 4% year-over-year.
Gross profit for the quarter decreased 13% to $7 million with a margin of 60.5%, compared to 66.6% in the prior year.
Loss from operations decreased 22% to $3.6 million.
Net loss for shareholders increased slightly to $4.7 million or $0.14 per share.
Revised full year guidance anticipates a decrease in total revenue by approximately 11% to 9% year-over-year to $46.6 million to $47.6 million.
报告了总季度营业收入1150万美元，同比下降4%。
季度毛利润下降13%，至700万美元，利润率为60.5%，而去年同期为66.6%。
经营亏损减少22%，至360万美元。
股东净亏损略有增加，达到470万美元，每股0.14美元。
修订的全年指导意见预计，总营收将同比下降约11%至9%，至4660万至4760万美元。
Business Progress:
业务进展：
Undergoing a strategic restructuring including a reduction of the U.S. workforce by 25%.
Introduction of the Ayon body contouring system; planning to submit a 510(k) to the FDA, expected to launch in the second half of 2025.
Announced promotion of Shawn Roman to Chief Operating Officer.
Expanding direct-to-consumer campaigns and initiatives to educate both physicians and patients on Renuvion technology.
正在进行战略重组，包括将美国员工数量减少25%。
推出Ayon塑身系统；计划向FDA提交510(k)申请，预计将于2025年下半年推出。
宣布将Shawn Roman晋升为首席运营官。
扩大面向消费者的直接推广活动和倡议，以教育医师和患者关于Renuvion技术。
Opportunities:
机会：
Projected increase in demand for Renuvion technology due to the side effects of GLP-1 drugs, leading to a growing market for surgical treatments of loose skin.
Anticipation of capturing new market shares and expanding the total addressable market in aesthetic surgery with the upcoming launch of the Ayon body contouring system.
预计由于GLP-1药物的副作用而导致对Renuvion技术需求增加，从而推动松弛皮肤手术治疗市场的增长。
期待通过即将推出的Ayon塑身系统捕获新的市场份额，并拓展美学手术领域的总体市场规模。
Risks:
风险：
Continued soft performance in generator capital sales attributed to macroeconomic pressures and competition from non-invasive aesthetic procedures.
Potential near term impacts on capital equipment sales as customers may postpone purchases in anticipation of the new Ayon system.
Dependency on the successful review and approval by the FDA of the new Ayon system, and effective integration of numerous surgical technologies.
发电机资本销售的低表现归因于宏观经济压力和来自非侵入性美容程序的竞争。
由于客户可能推迟购买以期待新的Ayon系统，可能对资本设备销售产生潜在的近期影响。
依赖于FDA对新Ayon系统的成功审查和批准，以及对多种外科技术的有效整合。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
